BACKGROUND: Because coronary artery vasculopathy (CAV) is a common cause of late cardiac allograft loss in humans, there is a need to develop and test non-invasive surrogate markers capable of detecting and predicting this disease entity. METHODS: We performed a cross-sectional analysis of immune-based surrogate markers in 65 primary cardiac allograft recipients with or without angiographically documented CAV. Anti-donor cellular immunity was determined by interferon gamma (IFN)-gamma enzyme-linked immunosorbent spot (ELISPOT) assays using donor HLA-derived peptides (indirect pathway), and anti-donor alloantibodies were detected by flow cytometry using HLA-coated beads. RESULTS: Anti-donor cellular and humoral immunity were detected more frequently in patients with CAV (17 of 32, 53.1%) than in controls (4 of 33, 12.1%) (p < 0.001). Anti-donor cellular and humoral immunity were detected in different sub-groups of CAV patients; peripheral blood lymphocytes (PBLs) from only 1 of 32 CAV patients reacted to donor peptides with simultaneous detection of peripheral anti-donor alloantibodies. CONCLUSIONS: Immune reactivity in cardiac transplant recipients with CAV differs significantly from those without CAV and the detected responses are heterogeneous in nature. Serial assessments of anti-donor immunity using different methods will be required to detect and possibly predict outcome in cardiac transplant recipients.
BACKGROUND: Because coronary artery vasculopathy (CAV) is a common cause of late cardiac allograft loss in humans, there is a need to develop and test non-invasive surrogate markers capable of detecting and predicting this disease entity. METHODS: We performed a cross-sectional analysis of immune-based surrogate markers in 65 primary cardiac allograft recipients with or without angiographically documented CAV. Anti-donor cellular immunity was determined by interferon gamma (IFN)-gamma enzyme-linked immunosorbent spot (ELISPOT) assays using donor HLA-derived peptides (indirect pathway), and anti-donor alloantibodies were detected by flow cytometry using HLA-coated beads. RESULTS: Anti-donor cellular and humoral immunity were detected more frequently in patients with CAV (17 of 32, 53.1%) than in controls (4 of 33, 12.1%) (p < 0.001). Anti-donor cellular and humoral immunity were detected in different sub-groups of CAV patients; peripheral blood lymphocytes (PBLs) from only 1 of 32 CAV patients reacted to donor peptides with simultaneous detection of peripheral anti-donor alloantibodies. CONCLUSIONS: Immune reactivity in cardiac transplant recipients with CAV differs significantly from those without CAV and the detected responses are heterogeneous in nature. Serial assessments of anti-donor immunity using different methods will be required to detect and possibly predict outcome in cardiac transplant recipients.
Authors: Lara Danziger-Isakov; Leonid Cherkassky; Hanni Siegel; Mary McManamon; Kristen Kramer; Marie Budev; Deirdre Sawinski; Joshua J Augustine; Donald E Hricik; Robert Fairchild; Peter S Heeger; Emilio D Poggio Journal: Transplantation Date: 2010-04-15 Impact factor: 4.939
Authors: Stuart C Sweet; Hyunsook Chin; Carol Conrad; Don Hayes; Peter S Heeger; Albert Faro; Samuel Goldfarb; Ernestina Melicoff-Portillo; Thalachallour Mohanakumar; Jonah Odim; Marc Schecter; Gregory A Storch; Gary Visner; Nikki M Williams; Karen Kesler; Lara Danziger-Isakov Journal: Am J Transplant Date: 2019-07-25 Impact factor: 8.086
Authors: Fang Li; Jennifer Wei; Nicole M Valenzuela; Chi Lai; Qiuheng Zhang; David Gjertson; Michael C Fishbein; Jon A Kobashigawa; Mario Deng; Elaine F Reed Journal: J Heart Lung Transplant Date: 2014-10-24 Impact factor: 10.247
Authors: I Ashoor; N Najafian; Y Korin; E F Reed; T Mohanakumar; D Ikle; P S Heeger; M Lin Journal: Am J Transplant Date: 2013-05-24 Impact factor: 8.086
Authors: R C Starling; J Stehlik; D A Baran; B Armstrong; J R Stone; D Ikle; Y Morrison; N D Bridges; P Putheti; T B Strom; M Bhasin; I Guleria; A Chandraker; M Sayegh; K P Daly; D M Briscoe; P S Heeger Journal: Am J Transplant Date: 2015-08-10 Impact factor: 8.086
Authors: Laura Codarri; Laure Vallotton; Donatella Ciuffreda; Jean-Pierre Venetz; Miguel Garcia; Karine Hadaya; Leo Buhler; Samuel Rotman; Manuel Pascual; Giuseppe Pantaleo Journal: J Exp Med Date: 2007-06-25 Impact factor: 14.307